Psychedelic-induced hypomania and mania: a systematic review and meta-analysis.
Mickael Eskinazi, Rayan Nasserdine, Romane M Cusin et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis examined the risk of hypomania and mania following exposure to serotonergic psychedelics in various populations. Among 23 studies, the prevalence of psychedelic-associated dysphoria/euphoria and manic symptoms ranged from 5.8% to 30%. The analysis indicated a 4% prevalence of subsequent transition to bipolar disorder in registry-based cohorts.
Key findings
- Rates of psychedelic-associated dysphoria/euphoria, hypomania, or mania ranged from 5.8% to 30%.
- The prevalence of subsequent transition to bipolar disorder was 4% (95% CI 2-8%; N = 7478).
- Manic symptoms were typically acute and self-limited when they occurred.
- Higher risks were identified among individuals with bipolar I disorder and familial vulnerability.
Why it matters
Understanding the potential risks associated with serotonergic psychedelics is crucial for clinicians, especially when treating individuals with bipolar spectrum vulnerabilities. This knowledge can inform patient selection and monitoring strategies during psychedelic-assisted therapies.